Here’s a polished English translation of the Chinese title: **”Endless Innovation, Growing Confidence | Mays Aesthetics Shines at the 14th National Minimally Invasive Medical Aesthetics Conference”** Alternatively, a more concise version: **”Innovation Unstoppable, Confidence Ever-Growing | Mays Aesthetics at the 14th National Minimally Invasive Medical Aesthetics Conference”**

Reshaping Personalized Beauty with a Century of Innovation

CHANGSHAJune 5, 2026 /PRNewswire/ — From June 4 to 7, 2026, Merz Aesthetics (hereinafter referred to as “Merz Aesthetics”), the world’s largest company focused exclusively on medical aesthetics^[1], showcased its numerous innovative products at the 14th National Minimally Invasive Medical Aesthetics Conference of the Chinese Association of Plastics and Aesthetics (hereinafter referred to as the “Conference”) held in Changsha. This marks the second consecutive year Merz Aesthetics has participated in this industry event. Dr. Owen Sunga, Executive Vice President and Global Head of Medical Affairs at Merz Aesthetics; Sylvia Lee, Senior Vice President of Asia Pacific and Head of China Business; and William Cui, General Manager of China, attended the conference alongside the Asia Pacific and China management teams.

As the medical aesthetics industry enters a new development phase characterized by “regulatory reshaping, technological breakthroughs, and evolving demands,” addressing the genuine needs of aesthetic seekers through deep insights and evidence-based medicine has become a critical question for the industry. In November 2025, Merz Aesthetics commercially launched two new products in China: XEOMIN^® (incobotulinumtoxinA for injection) and RADIESSE^® (calcium hydroxylapatite microspheres facial injectable). These join the previously launched BELOTERO^® (cross-linked hyaluronic acid gel for injection) product line, completing Merz Aesthetics’ comprehensive facial injectable portfolio. Aligned with the conference’s theme of “Returning to the Essence of Medicine,” Merz Aesthetics presented comprehensive solutions addressing various facial needs.

Sylvia Lee, Senior Vice President of Asia Pacific and Head of China Business at Merz Aesthetics, stated: “China has always been a key market in Merz Aesthetics’ Asia Pacific and global strategy. With the successful launch of our star products and the rapid expansion of our team in China, our business here has entered a new phase of development. Leveraging our cutting-edge pipeline and sustained investment in clinical science in China, Merz Aesthetics is committed to more comprehensively and swiftly meeting the increasingly diverse and sophisticated needs of Chinese aesthetic seekers, while ensuring product quality and safety.”

Star Products Showcase | Highlighting Personalized Aesthetics

In the booth design for this conference, Merz Aesthetics used spatial language to convey its ongoing exploration between technological innovation and natural aesthetics. Visitors entering the booth could intuitively perceive Merz Aesthetics’ century-long heritage and cutting-edge layout, and engage in immersive experiences through various interactive installations.

The booth featured a dynamic, expansive immersive screen as the first touchpoint at the entrance, evoking imagery of abundance, nature, confidence, and vibrant aesthetics through flow and convergence. The company history wall, VR (virtual reality) immersive experiences, fun interactive installations, and other rich content showcased Merz Aesthetics’ relentless pursuit of technological innovation and natural beauty.

Through artistic installations, Merz Aesthetics transformed rigorous science into perceptible aesthetic expressions, allowing product value to be concretely realized within the spatial experience.

Among them, XEOMIN^®, the world’s first pure+ botulinum toxin free from impurities*, is indicated for the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults under 65 years of age.

RADIESSE^®, through its unique non-inflammatory mechanism of action, provides comprehensive rejuvenation improvement by “activating the native, restarting the whole.”

BELOTERO^® utilizes the unique BBMT (Belotero Biomimetic Matrix Technology) to mimic natural skin from three dimensions: structure, function, and behavior. Currently, BELOTERO^® products launched in China include BELOTERO^® BALANCE and BELOTERO^® VOLUME, indicated for injection into the mid-dermis to correct moderate nasolabial folds and into the deep dermis or subdermis to correct severe nasolabial folds, respectively.

Dr. Niamh Corduff, Australian plastic surgery expert, commented: “As medical aesthetics concepts evolve, the industry is increasingly focusing on the real needs of aesthetic seekers. Merz Aesthetics’ products, used alone or in combination, can meet individual needs. XEOMIN^®, with over 20 million treatment experiences globally^[2], offers a pure anti-wrinkle option. Recent studies show that RADIESSE^® can significantly promote the regeneration of collagen and various key proteins in the extracellular matrix, improving solar elastosis (a major manifestation of photoaged skin). BELOTERO^® is dedicated to helping aesthetic seekers achieve seamless, natural beauty in every detail.”

Accelerating Forward | Leading the Future of the Industry

Merz Aesthetics is dedicated to helping people look better, feel better, and live better, empowering aesthetic seekers and industry professionals to achieve confident authenticity. The company is committed to meeting the personalized needs of aesthetic seekers by actively listening to their thoughts and needs, combining scientific research and clinical expertise to provide comprehensive solutions, and collaborating with partners to promote healthy industry development.

During the conference, Merz Aesthetics brought together multidisciplinary experts for in-depth discussions on key topics such as the standardized use of botulinum toxin and resistance, advancing the continuous improvement of the ASCEND expert consensus in China. Additionally, Merz Aesthetics, in collaboration with the Plastic and Aesthetic Committee of the Chinese Non-government Medical Institutions Association, released the “RADIESSE White Paper on Clinical Applications and Industry Development in China.” This white paper integrates international expert consensus and clinical guidelines based on consumer survey results in the Chinese market, providing clinical application and academic decision-making references for medical aesthetics practitioners.

William Cui, General Manager of Merz Aesthetics China, stated: “The Chinese medical aesthetics market is entering a more mature and standardized development phase, placing higher demands on product innovation, clinical practice, and industry standards. With our rich product portfolio and innovative solutions, Merz Aesthetics will continue to collaborate with industry partners in China to drive the synergistic upgrade of cutting-edge technology and standardized applications, helping the industry move toward a new stage of high-quality development.”